Expertise in
14
conditions

Dr. Steven Dibiase

Radiation Oncology
CHRISTUS Cancer Clinic
323 E Hawkins Pkwy Ste 1-A, 
Longview, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
14
conditions
CHRISTUS Cancer Clinic
323 E Hawkins Pkwy Ste 1-A, 
Longview, TX 

Overview

Steven Dibiase is a Radiation Oncologist practicing medicine in Longview, Texas.

Dr. Dibiase is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Angiosarcoma of the Scalp.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 10 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in NJ

Hospital Affiliations

New York-Presbyterian/queens

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

CHRISTUS Cancer Clinic
323 E Hawkins Pkwy Ste 1-A, Longview, TX 75605

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Enrollment Status: Recruiting
Publish Date: August 27, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States.
Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States.
Journal: Advances in radiation oncology
Published: October 09, 2018
Similar Doctors
Expertise in
8
conditions
Dr. Joseph Hodges
Radiation Oncology
Expertise in
8
conditions
Dr. Joseph Hodges
Radiation Oncology

Longview Cancer Center Mobile Pet

1300 N 4th St, 
Longview, TX 
 (1286.8 miles away)
903-757-2122
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Hodges is a Radiation Oncologist practicing medicine in Longview, Texas. He has been practicing medicine for over 17 years. Dr. Hodges is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Prostate Cancer, Familial Prostate Cancer, and Breast Cancer.

Expertise in
8
conditions
Dr. Bernard Taylor
Radiation Oncology
Expertise in
8
conditions
Dr. Bernard Taylor
Radiation Oncology

Longview Cancer Center Mobile Pet

1300 N 4th St, 
Longview, TX 
 (1286.8 miles away)
903-757-2122
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bernard Taylor is a Radiation Oncologist practicing medicine in Longview, Texas. Dr. Taylor is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Prostate Cancer, Familial Prostate Cancer, and Breast Cancer.

Expertise in
32
conditions
Dr. Chiachien Wang
Radiation Oncology
Expertise in
32
conditions
Dr. Chiachien Wang
Radiation Oncology

Radiation Oncology Services Apmc

2600 Kings Hwy, 
Shreveport, LA 
 (1241.3 miles away)
318-212-4639
Languages Spoken:
English
See accepted insurances

Chiachien Wang is a Radiation Oncologist practicing medicine in Shreveport, Louisiana. Dr. Wang is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Astrocytoma, Pleuropulmonary Blastoma, and Posterior Fossa Tumor.

Frequently Asked Questions about Dr. Steven Dibiase

How do I make an appointment with Dr. Steven Dibiase?

You can book an appointment with Dr. Steven Dibiase by calling their office at 903-544-6888. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Steven Dibiase a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Steven Dibiase is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Steven Dibiase specialize in?

While Dr. Steven Dibiase is a Radiation Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Steven Dibiase participate in research or clinical trials?

Yes. Dr. Steven Dibiase has published 2 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Steven Dibiase's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Steven Dibiase accept my insurance?

Dr. Steven Dibiase accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 903-544-6888 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dibiase's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile